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Triple negative breast cancers (TNBC) are closely related to basal-like cancers and
classified based on their molecular signatures and their progenitor cell type. TNBCs lack
the presence of three common types of receptors known to fuel breast cancer growth:
estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor
receptors 2 (HER2neu). TNBC represent 10-20% of all molecular breast cancer subtypes.
Even though genomic and transcriptome analyses show that many of the molecular
signatures associated with TNBC are not related to ethnicity, clinicians and researchers
find that African American (AA) TNBC women have higher mortality rates compared to
Caucasian (CA) women. The high mortality rates are linked to socioeconomic factors like
access to adequate healthcare, but researchers are exploring the possibility that genetic
differences between AA and CA patients may also play a role in racial disparities.
Microarray analyses have been instrumental in characterizing TNBC and many other types
of breast cancer. Related to TNBC, microarray analyses (a) validate the negative receptor1
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status of the cancers (b) identify and define the six sub-categories of TNBC validating the
heterogeneity of the cancers as defined by Lehmann et al and (c) the microarray gene
expression platform is proving to be useful towards determining genes differentially
represented in AA and CA TNBC. Our approach is to use the microarray platform (and a
cell line model) to further examine the differences between the transcriptomes of CA and
AA women. For more accurate transcriptome comparisons, we’ve identified and compared
AA Basal-A TNBC to CA Basal-A TNBC, and separately AA Basal-B TNBC compared to
CA Basal-B TNBC. Bioinformatic analyses show that TCEAL8 and TCEAL9 genes, both
located on X-chromosome are differentially expressed in AA compared to CA TNBC. The
EFHD1 gene is identified as differentially expressed in AA Basal-B compared to CA BasalB TNBC. These data serve as a preliminary study towards further characterizing molecular
differences between the transcriptomes of AA compared to CA TNBC patient populations.
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CHAPTER 1
INTRODUCTION
Cancer
Cancer is defined as a disease where cells undergo differentiation, leading to
uncontrollable growth and in some cases metastases to distinct locations in the body (1).
The human body is made up of trillions of cells, all of which can mutate and ultimately
differentiate into cancerous cells (1). Mutations within a cell can activate oncogenes or
deactivate tumor suppressor genes that affect differentiation, cell cycle signaling pathways,
cell death mechanisms and yet undefined processes (2). The cancerous cell proliferates,
continues to differentiate, and ultimately becomes invasive based on its genotype (3). The
cancers become harmful when their growth interrupts the natural survival functions of the
primary and metastatic organs (3).
Cancers develop into invasive tumors in stages (Figure 1). The first stage of
development is hyperplasia, which is defined as an increase in the size of the tissue caused
by an increase in cellular proliferation (3), which itself is not a cancer. The off spring of
these cells then grow and differentiate, displaying a ‘somewhat abnormal’ phenotype and
genotype; this stage is called dysplasia (3). Dysplastic cells that continue to mutate and
stay within the tissue of origin are called in-situ tissues (3). In-situ tissues can remain in
the site from which they originate, but if they continue to mutate and convert to cancers,
shed into the blood and invade nearby tissues, they are described as malignant invasive
1
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cancers (3). To determine the progression of cancers, pathologists will also describe a
numeric ‘staging’ for the cancers as listed below:
Cancer Number Staging:
Stage 0- in situ, abnormal tissue localized to site of origin and has not spread
Stage 1-small cancer, that has not spread beyond its original boundaries
Stage 2-larger cancer, that has not spread beyond its original boundaries
Stage 3-larger cancer, that may have spread to the surrounding lymph nodes
Stage 4-the cancer has spread (i.e., metastasized to secondary organs

Figure 1:

Tumor Development Stages
Tumor cells divide in stages which can ultimately invade other tissues or
shed into the blood and travel throughout the body establishing tumors in
other areas (8).

Common Types of Cancer
In 2020 alone, cancer caused nearly 10 million deaths making it the leading cause
of death worldwide (4). The most common types of cancer are breast, lung, colon, prostate
cancers and skin (4). Breast cancer is one of the most common types of cancer in women
and leads all other types of cancers in cancer death rate among women (4). Over 200 types
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of cancer have been identified but of these types of cancers breast cancer was the leading
cancer diagnosed in the United States (5). The focus of my research is to better characterize
Triple Negative Breast Cancer (TNBC) a type of breast cancer that has higher fatality rates
in women of African descent. The different types of breast cancer will be discussed in the
following sections. Lung cancer is a form of cancer that involves the formation of cancer
cells in the lung tissue. It is the second most diagnosed cancer in the United States and
causes the most deaths of all other types of cancers making up 25% of all cancer deaths
(6). Colon cancer or Colorectal cancer (CRC) is the third most diagnosed cancer in the
United States and is the second deadliest cancer type among men and women (7). CRC has
steadily declined in individuals over 50, mainly due to cancer screening and therapeutic
advancements (7). Prostate cancer is the most common type of cancer diagnosed in men,
worldwide, and is the fourth highest cause of cancer death in men (8). Most prostate cancers
tend to be less aggressive and grow much slower than other types of malignancies, and
when limited to the prostate these cancers are generally considered localized and curable
(8). Related to Skin Cancer, approximately 3.6 million new patients of Basal Cell
Carcinoma, 1.8 million new patients of Squamous cell carcinoma, 197,000 new patients
with Melanoma and 3000 new cases of Merkel Skin cancer are diagnosed world-wide each
year (https://www.skincancer.org/skin-cancer-information/). The majority of these cases
are caused by over-exposure to the sun’s ultraviolet light and UV rays associated with
tanning beds. Both light sources damage DNA leading to defective DNA repair
mechanisms and cancers.
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Breast Cancer
Cancer is typically named after the body part it affects, so breast cancer is the
uncontrollable growth of cells in the breast tissue (9). Breast cancer in women accounts for
1 in 10 newly diagnosed types of cancer each year in the United States and is one of
deadliest forms of cancer for women in the world (10). Breast cancer can develop silently
for years. Most breast cancers are detected during routine screenings while others are
discovered by the patient after finding lumps in the breast (10). The anatomy of the breast
(Figure 2) consists of milk producing glands that lie on the pectoralis major muscle behind
the chest wall (11). A collection of approximately 15-20 lobes forms in a circular
arrangement, while fat surrounds the lobes determining the size and shape of the breast
(10). The lobes are interconnected by thin tubes called breast ducts, which carry milk
produced by the lobes to the nipple (12). Most breast cancers tend to develop in the ducts
of the breast tissue while others begin in the lobules and other tissues of the breast (9). The
metastatic form of breast cancer can penetrate the boundaries of breast tissue, migrate and
develop in other tissues of the body including the lungs, brain, bones and liver (12). Early
detection of breast cancer greatly improves the prognosis of the disease. Mammography
and other screening techniques like Magnetic Resonance Imaging (MRI) are proving to be
affective in the detection of breast cancer, increasing patient survival rate by over 80%
(12). Alternatively, breast cancer statistics are drastically different in underdeveloped
countries. Underdeveloped countries lack the resources and infrastructure needed for early
detection of breast cancer, as a result, early detection rates are lower and mortality rates
are higher compared to that in developed countries (13). According to The World Health
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Organization (WHO), early detection of breast cancer greatly improves breast cancer
outcome and survival and is the foundation of regulating the disease (13).

Figure 2:

Diagram Illustrating the Anatomy of the Female Breast

Breast Cancer Treatment
Breast cancer treatments typically depend on the type and stage of the cancer.
Modern medicines and medical therapies have been employed to prevent and treat breast
cancer growth and development (14). Some of the most common forms of breast cancer
treatment include surgery, chemotherapy, hormonal therapy, targeted biological therapy,
and radiation therapy. Often, people with breast cancer undergo one or more kinds of
treatments, and different breast cancer specialists work together to treat the patient (14).
The leading approach to treating breast cancer today involves ‘breast-conservation surgery’
(to remove the cancer and the immediate surrounding areas) followed by an adjuvant
therapy (i.e., treatment after the primary treatment) to decrease the risk of secondary
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malignant growths and ensure a full recovery (15). Radiation and chemotherapy treatments
are provided after surgery, to destroy any cancer cells not observed during the surgical
procedure; this reduces the risk of a localized reemergence of cancer (15). Radiation
therapy involves exposing the cancer cells to high levels of direct radiation to shrink the
tumor. Side effects to radiation therapy include decreased sensitivity in the breast tissue
along with cosmetic and other problems in the treated areas of the tumor (15). Conventional
targeted therapy (like tamoxifen) is used to effectively treat estrogen and progesterone
positive patients, and trastuzamab is used to treat HER2 positive patients.
Treatment of TNBC
Because cells associated with TNBC cancers are receptor-negative, the targeted
therapies noted above are not effective and cannot be utilized for treatment of TNBC.
Radiation and chemotherapy are most often used for treatment of TNBC patients. Current
neoadjuvant chemotherapy has proven efficacy in the treatment of early-stage and
advanced TNBC.
A review published by Lehmann et al. titled “Clinical Implications of Molecular
Heterogeneity in Triple Negative Breast Cancer” in 2015 set out to review the molecular
heterogeneity of TNBC and how this diversity impacted previous and future clinical trials
(16). TNBCs lack ER, PR and HER2 gene expression making them insensitive to antihormonal and HER2 targeted therapies (16). Lehmann found that about 30% of patients
diagnosed with TNBC benefit from neoadjuvant chemotherapy and those that experienced
a pathological complete response during surgery showed significant improvements in
overall survival (16). Typically, patients with TNBC have much lower survival rates than
other breast cancer diagnosis even though they show a better response to chemotherapy
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(16). This is likely due to chemotherapy-resistant tumors that remain after treatment for
many TNBC patients (16). Results from these and other studies by Lehmann et al studies
support the utility of examining precise genetic differences among TNBC patients so that
a more ‘targeted treatment strategy’ can be use. This approach can only be applied if the
genetics of TNBC patients are more accurately characterized, which the Lehmann
laboratory has accomplished. Much of my research is based on analyzing TNBC using the
Lehmann classification, ‘instead of analyzing the cancers as a single homogenous group’.
My aim is to (a) identify genetic differences between African American (AA) and
Caucasian (CA) TNBC that will be studied for their potential role in contributing to cancer
in AA patients. Ultimately, our aspiration is that genes discovered in our laboratory will
lead to strategies that impact patient survival.
Breast Cancer Types
Breast cancer is not just one type of cancer. There are different forms of the cancer
which are named depending on the original location of the cancer and its progenitor cell
type (17). The type of breast cancer will ultimately determine the type of treatment or
therapy. Breast cancers can be defined based on their pathology and more recently with the
advent of molecular analysis tools (like DNA microarrays), breast cancers are defined
based on molecular descriptions.

Breast Cancer Types Based on Pathological Diagnoses
The pathological distinctions of breast cancers are summarized below. Molecular
characterizations of breast cancers are described later.
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•

Lobular Carcinoma in Situ (LCIS): defined as an abnormal, in situ cell
growth in the lobules.

•

Ductal Carcinoma in Situ (DCIS): non-invasive, in situ, originates in
the milk duct; incidence up to 20% of cancers diagnosed.

•

Invasive Ductal Carcinoma (IDC): invasive, infiltrating ductal cancers,
occurring in up to 80% of cancer diagnosed.

•

Tubular Carcinoma of the Breast: a subtype of the IDC cancers. The
cells have a tubular configuration, with an incidence of 8%-27% in
patients.

•

Medullary Carcinoma of the Breast: rare invasive ductal carcinomas
with resemblance to the brain’s medulla. They occur in ~3% of
patients.

•

Mucinous Carcinoma of the Breast: rare cancers described as ‘floating
in a pool of mucin’. The cancer begins in the milk ducts.

•

Papillary Carcinoma of the Breast: rare invasive carcinomas with
finger-like projections, occurring in approximately 1-2% of patients.

•

Cribriform Carcinoma of the Breast: rare, normal-looking invasive
cancers named based on their cribriform-like configurations.

•

Invasive Lobular Carcinoma (ILC): invasive cancers that originate in
the lobules of the breast. They occur in ~20% of patients.

•

Inflammatory Breast Cancer (IBC): rare very aggressive, invasive
cancer that spread within the breast tissue in ‘sheets’ instead of lumps,
making the cancers difficult to detect and ultimately treat.
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•

Phyllodes Tumors of the Breast: rare tumors, occurring in less than 1%
of patients. The cells grow in a leaf-like configuration.

•

Paget’s Disease of the Nipple: rare breast cancer involving cancer
around the nipple and ducts draining towards the nipple.

•

Male Breast Cancer: Breast cancers in men are rare, occurring at a rate
of less than 1%. Breast cancers in males are smaller than those observed
in females, but they can be equally as invasive.

Breast Cancer Types Based on Molecular Description
The first DNA microarray was proposed by Patrick Brown in early 1980’s (ref),
and manufactured as large scale in the 1990’s. Much of the data related to the molecular
description and signaling pathways associated with breast and other cancers are identified
using the microarray platforms. Microarrays allow for more detailed biological
characterization of the genome and transcriptome of cellular mechanisms, which in turn
allow for more accurate diagnoses and subsequent treatment (18). The molecular
descriptions of breast cancers are summarized below. There are six molecular subtypes of
breast cancer which include (Figure 3):
•

Luminal A- cancers are defined as positive for estrogen receptor and
progesterone

•

and negative for HER2 gene expression and low Ki-67 levels.

Luminal B- cancers are defined as positive for estrogen receptor and
progesterone receptor and for positive for HER2 or negative for HER2 with
high Ki-67 levels.
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•

HER+ve (HER2neu/ErbB2)- cancers are enriched in HER2 levels and
negative for estrogen and progesterone receptor expression.

•

Normal-like-cancers are similar to Luminal A but follow normal breast
profiling.

•

Triple negative- negative for estrogen, progesterone and HER2 expression.
Expanded description in the section below.

•

Claudin low-cancers display low claudin (cell adhesion) expression and high
epithelial-mesenchymal transition genes.

Figure 3:

Molecular Subtypes of Breast Cancer
Triple negative breast cancer is one of the six types of breast cancer based
on molecular characterization (6).
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TNBC (triple negative breast cancer) are negative for the three receptor genes
estrogen receptor, progesterone negative and HER2neu. Of the 6 molecular subtypes,
TNBC patients represent ~15% of breast cancers and have low 5-year survival rates.
Although TNBC are characterized as negative for 3 receptor genes, Lehmann et al show
the subtype can be further divided into six sub-categories based on clustering signatures
and molecular gene expression (19). DNA microarrays were utilized to further characterize
TNBC and identify the various sub-categories. Lehmann et al. identified: (a) two basal-like
types (designated BL1 and BL2)- basal type 1 (BL1) includes over-expression of genes
involved in signaling pathways related to Ribonucleic acid (RNA) polymerase processes,
cell division and cell cycle regulation. Patient samples characterized as Basal type 2 (BL2)
genotype are thought to be of myoepithelial origin, including genes associated with growth
factor signaling processes, gluconeogenesis, and glycolysis. (b) luminal androgen receptor
or molecular apocrine group (LAR)- this group includes estrogen receptor samples with
over-expression of androgen receptor, and other genes involved in hormonal regulation.
(c) an immunomodulatory group- samples characterized in the immunomodulatory (IM)
category appear like medullary breast cancers and are enriched in genes involved in
immune signaling pathways, cytokine signaling, natural killer cell pathway and antigen
identification and processing. (d) a mesenchymal (M) and (e) mesenchymal stem-like
group (MSL) the group- The M and MSL groups are enriched in genes associated with cell
motility, mesenchymal-like differentiation, proliferation, and extra-cellular matrix
proteins. There are significant implications to these studies. Lehmann et al suggested that
‘by defining TNBC based on unique signatures, driver signaling pathways can be identified
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and used as pharmacological targets. These transcriptome distinctions are what I refer to
as Lehmann classification in this text.
Anatomical Location of TNBC Progenitor Cells in Breast Tissue
Breast cancer can be characterized by genetics, and by pathology. A normal
microscopic representation of breast tissue is given in Figure 4 (20). Data suggest the
progenitor cells for TNBC line the outer regions of the luminal regions. These cells are
described as basal-like cells, which surround the myoepithelial and luminal cells, each
which are closer to the breast lumen.

Figure 4:

Diagram of the Breast Tissue and Luminal Ducts
Anatomical location of Triple Negative Breast Cancer can be found in the
basement membrane of the luminal ducts (7).

Triple Negative Breast Cancer and Racial Disparities
TNBC are based on molecular characterizations. The primary focus of my research
is to further characterize the cancers. We have several experimental approaches aimed at
understanding the cancers. Data show racial disparity in AA compared to CA patients. We
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will examine the transcriptome of AA and CA samples, with the goal of identifying genes
differentially expressed between the patient populations.
Metadata analyses show that racial disparity is due to three principal determinants
(Figure 5): (a) the difference in obesity among the two ethnic groups (b) socioeconomic
factors such as under representation in clinical trials or simply not having access to suitable
hospital resources and (c) biological determinates related to race. The biological
determinants include differential mutations associated with BRCA1 and/or p53 genetic
factors, and differential expression of cancer stem cell genes like ALDH1 and Wntsignaling pathway genes (21). This research also focused on interrogation of samples
isolated from AA and CA patients in search of defining biological differences between the
two ethnic groups.
There is a higher incidence of TNBC in AA and women of African descent
compared to CA and women of European descent. In 2011, a study by Lehman and others
showed that TNBC was not just one type of cancer in patients, but a complex heterogenous
type of breast cancer that could be subdivided into at least 6 different subdivisions (19). In
addition to addressing the complexity defined by Lehmann, we are addressing the
biological differences between AA and CA TNBC genotypes based on Lehmanns’
classification.
A disproportionate number of the earlier TNBC studies were performed analyzing
CA patient samples. So, we have a lot to learn related to the biological processes in AA
TNBC. Since much of what is known about TNBC has been obtained following microarray
analyses, we will utilize DNA microarray to further compare the ethnic populations. We
will characterize TNBC in CA compared to AA patients, focusing on separate analysis of
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Basal A and Basal B subgroups that define the TNBC with the aim of identifying gene
expression patterns that contribute to the disparity observed between the two races.
Identifying the differences between the two ethnic populations could lead to a better
understanding of TNBC tumors in general as well as the development of biomarkers and
therapeutic targets to improve patient survival. Our hypothesis is that there are genetic
signatures that distinguish TNBC in CA compared to AA patients which can be identified
by comparing sub-populations within the TNBC subtype. Our analysis can be summed up
into one principal approach. We aim to identify differentially expressed genes related to
either Basal A or Basal B subtypes associated with CA and AA cell lines.

Figure 5.

Racial Disparity
TNBC in women of African-descent vs Caucasian based on Obesity,
Socioeconomic determinants, and Biology (genes) (25).

CHAPTER 2
LITERARY REVIEW
An incredible number of studies show that AA patients have a higher incidence of
TNBC and age-adjusted mortality. AA patients are twice as likely to be diagnosed with the
disease and more likely to die from breast cancer. Many investigators suggest that
biological factors and not just socioeconomic factors contribute to these disparities (22).
Data confirms that the microarray experimental platform is the best experimental approach
to use for this type of study. These analyses are also best performed using approaches that
consider the genetic heterogeneity and complex genetic signatures of the TNBC. As a
result, comparative analyses of CA versus AA patient must consider the heterogeneity of
TNBCs as defined by Lehmann et al. Our analyses are based on both microarray and the
Lehmann approach. Once TNBC are defined based on genetic heterogeneity, then more
reliable signatures distinguishing CA vs AA can be found and considered as therapeutic
strategies. We must emphasize that other laboratories are aware that this is the most logical
approach towards better characterizing differences based on ethnicity.
Significance of Lehmann et al. Studies
Even though TNBC is defined as negative for 3 receptors it is a molecularly diverse
disease (23). This diversity limits the success of traditional targeted therapies in patients
(23). Studies by Lehmann et al have been instrumental in further characterizing the
15
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cancers. Lehmann used DNA microarray bioinformatic analyses to further divide TNBC
into six sub-categories defined by clustering of molecular gene signatures. This unique
characterization of the transcriptional subtypes of TNBC has led to a more ‘focused use of
conventional therapies and identification of potential biomarkers being studied as targeted
therapies for TNBC patients (24).

New biomarkers (identified using the Lehmann

approach) are currently being studies for their use as therapies for TNBC patients (23).
Genomic and Socioeconomic Relationship of TNBC Among AA vs CA
Data are clear in that disparities in AA compared to CA are multifactorial, complex
and related to both socioeconomic and biological factors. The socioeconomic factors are
related to AA’s predisposition to diseases like diabetes and hypertension, somewhat higher
levels of obesity and health care disparities based on access to healthcare like
mammographies, delivery of treatment and psychological and cultural factors. These
factors have been studied in recent years and found to enhance or inhibit the outcome of
the biological factors (25). In a 2013 study by Danforth entitled “Disparities in breast
cancer outcomes between Caucasian and African American women: A model for
describing the relationship of biological and nonbiological factors”, he suggested that
many of the nonbiological disparities between AA women and CA women could be
modified. Once modified, the nonbiological factors could drastically improve the outcome
of the biological factors (25). The biological factors are thought to be mostly related to
differences in the incidence of BRCA1 and p53 mutations, variations in Wnt signaling
pathways and other cancer stem cell signaling irregularities (ref).
The socioeconomic and genetic factor disparities of TNBC are widespread and
affect women of African descent not just African American women. One study showed
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that TNBC was the most dominant cancer diagnosis in sub-Saharan Africa and in 22
countries throughout the America’s and Caribbean (Figure 6) (22). The higher risk of
TNBC in African American women and sub-Saharan women versus CA and European
women further suggest that specific genetic components of geographically defined African
heritage are associated with hereditary susceptibility of TNBC carcinogenesis (26).

Figure 6:

TNBC Frequency Among Women of African Descent vs Women of
European Descent

Continued Review of Gene-related Factors Related to Racial Disparities
At this point, many of the studies demonstrating differences in dysregulation,
differential gene expression and genomic mutations in AA compared to CA TNBC patients
are merely observations, based on large scale analyses of archival datasets. In one such
study p53 mutations were observed in >45% of AA compared to 27% of CA, MLL3 was
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observed in 12% of AA compared to 6% of CA, and PIK3CA mutations in 23% of AA
compared to 34% of CA (Ademuyiwa et al.). The p53 gene is the most frequent mutation
found in cancer, MLL3 is a tumor suppressor gene deleted in myeloid leukemia, and
PIK3CA is associated with the PI3K pathway which is also frequently altered in cancers.
In a separate study Lee et al. (27) identified the gene resistin overexpressed in AA. Resistin
is secreted by adipocytes and is suspected of linking obesity to type II diabetes leading to
an intriguing hypothesis connecting obesity to a molecular signature in AA patients. In yet
another study, Field (28) matched tumors based on pathological characteristics and
observed CRYBB2, PSPHL, and SOS1 genes differentially expressed in AA compared to
CA patients. The three genes are shown to be involved in cellular growth and
differentiation, metastasis and invasion and immune response: another intriguing study
correlating the biological characteristics of TNBC in AA patients with functional pathways
and genes.
Epidemiological Risk of TNBC in AA Women
Many epidemiological risk factor differences have been identified as associated
with TNBC in AA women vs CA women. It should be mentioned that these are correlative
studies. Reproductive factors like menstruation beginning at younger ages and younger
ages of full-term pregnancy, higher exposures to societal inequality, and shorter duration
or a complete lack of breast feeding are thought to contribute to epidemiological
differences in TNBC disparities. In addition, the size and shape of the body like higher
body mass index and waist to hip ratio correlate with the epidemiological differences in
TNBC disparities (29). Sturtz and colleagues evaluated the differences in epidemiological
factors and gene expression profiling between AA women and CA women (29). This
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evaluation was referred to as the Clinical Breast Care Project. The investigators examined
the incidence of obesity, estrogen exposure, breastfeeding, diet and physical activity and
co-morbidities with TNBC status (29). They found that of the 1064 AA women and CA
women evaluated 15% of the women had TNBC. Of the women with TNBC, the incidence
in AA patients was 28%, compared to an incidence of 12% in CA patients (29).
Furthermore, the frequency of TNBC was higher in premenopausal AA women (53%)
compared to CA women (42%) (29). They also found that AA women were more likely to
be obese and that caffeine and alcohol use was significantly lower in AA women (29).
Another study performed Trivers et al sought to evaluate whether anthropometrics (i.e.,
science related to physical size and form), demographics and reproductive history were
associated with distinct breast cancer subtypes (30). They analyzed 460 women, 116 black
women and 360 white women, all with different subtypes of invasive breast cancer (30).
The different types of breast cancers were grouped as TNBC (ER-,PR-, HER2-), (ER-,PRHER2+), (ER/PR+, HER2+), (ER/PR+, HER2-) (30). They found that women with TN
tumors were more likely to be obese and that no matter the HER2neu status ER-PR- tumors
were more likely associated with AA women, younger age at first birth, having a recent
birth and being overweight (30). Collectively, these data suggest both socioeconomic and
biological factors contribute to disparities between AA compared to CA TNBC patients.
The multifactorial nature of the disease makes discovery of a ‘single cause’ a daunting task.

CHAPTER 3
DESIGN OF THE STUDY
Summary Statement
Data examined in this thesis are based on the bioinformatic analyses of subsets of
AA compared to CA TNBC cell lines and patient samples previously processed using DNA
microarray platforms. All datasets were extracted from Gene Expression Omnibus (GEO)
associated with the National Center for Biotechnology of the National Institutes of Health.
Rationale for Selection of the Cell Lines Used in this Study
Prior to the experimental results published by Lehmann et al. (19), practically all
experimental analyses of TNBC were based on treating TNBC as a single unit with limited
regards to the cancer’s heterogeneity and biological complexity. Lehmann wasn’t the first,
but his studies were one of first to elegantly demonstrate that the single TNBC subtype
could be further characterized based on clustering of precise genetic signatures. Further
characterization of TNBC can lead to more accurate results when comparing TNBC
patients to each other, and when comparing TNBC patient transcriptomes to other breast
cancer subtypes. Our (and other’s) approach to analyses of AA to CA patients are based on
considering TNBC sub-categories as defined by Lehmann et al.
We were aware that a limited number of AA TNBC cell lines were available for
this study. So, we first identified TNBC cell lines isolated from AA patients (as defined by
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references documented at atcc.org and GEO) and grouped them according to Lehmann’s
designation. To allow for accurate comparisons, we identified CA TNBCs that closely
resembled the AA based on molecular signatures (Table 1).
Table 1: Lehmann Classification and Genetic Characterization of TNBC

On the far right is the genetic characterization of each of these subtypes. In the
center of the diagram, we have cell lines that have been isolated from patients and
associated with their respective subtypes. The cell lines that we examined for our study are
designated by the arrows. The African American cell lines are designated by the arrows
with the red boxes and the Caucasian cell lines are designated with just an arrow. The top
four arrows are the cell lines that are being compared for the Basal A group and the bottom
three arrows are the cell lines of the Basal B group.
Table 1 details the 6 sub-categories of TNBC as defined by Lehmann (19). On the
far left of the table is the Lehmann classification of the types of TNBC. All cell lines in the
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Table 1 are TNBC and have been characterized based on gene analyses. Each of the subcategories are characterized based on Genetic abnormalities and Mutations. The particular
cell line associated with their respective subtype is noted in the center column of the Table.
The cell lines that we examined for our study are designated by the arrows. The AA cell
lines are designated by the arrows with the red boxes and the CA cell lines are designated
with just an arrow. The ethnicities of the cell lines were documented by references available
at attc.org and GEO. These cell lines were grouped according to their genetic similarities
based on Lehman classification, so that we could compare genetically similar AA to CA
patient cell lines. Using this approach, we can infer that after our analyses, to some degree,
differential gene expression is related to race. Cell lines in the top portion of the table are
designated Basal A group; four cell lines are included in this group. Cell lines in the bottom
portion of the table are designated Basal B; three cell lines are included in this group. It’s
important to note that there are limitations of my research; there are a limited number of
AA TNBC cell lines available for study. The only well-defined AA cell lines are the ones
designated here. The summary of the AA vs CA cell lines used in our study are given in
Table 2. The DNA microarray experimental platform was utilized to interrogate and
compare transcriptomes between AA vs CA cell lines. Raw transcriptome datasets for the
cell lines were obtained from GEO. The precise GEO raw data file for each cell line is
given in the DNA microarray Section below.
Table 2 is a summary of the TNBC cell lines used for the Basal A comparison and
the Basal B comparison in the study. Basal A cell lines are defined as basal-like and
immunomodulatory characteristics. Basal B cell lines are defined by their mesenchymal /
stem-like characteristics.
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Table 2:

Summary of the TNBC Cell Lines

•        Basal A: two groups to separately compare (ie, group 1 vs group2)
•       
Group 1 (CA cell lines)-included HCC1143 and HCC1187
•       
Group 2 (AA cell lines)-included MDA MB468 and HCC70
•        Basal B: two groups to compare (ie, group 1 vs group 2)
•      
Group 1 (CA cell lines)-included MDA MB231 and MDA MB436
•       
Group 2 (AA cell lines)-included MDA MB157)
DNA Microarray Analyses
GEO Source for the DNA microarrays for each cell line (raw data (not normalized).
The ‘wet-lab’ microarray experiments were not performed by our laboratory. The
microarray dataset for each cell line was obtained from GEO. Once in GEO, we used the
search terms ‘microarray and triple negative’ to identify cell lines processed using
microarrays. After we identified TNBCs processed using the microarray platform, we
searched individual datasets for AA and CA cell lines. The original GEO dataset
information is given below (in the event investigators wish to locate and download the
files). Duplicate sources were identified for some cell lines. Basal A cell line GEO
datasets: GSM1589133 (HCC1143), GSM276023 (HCC1143), GSM1589134 (HCC1187),
GSM1589146 (MDA MB468), GSM276009 (MDA MB468), GSM158914 (HCC70),
GSM276013 (HCC70). Basal B cell line GEO datasets: GSM1589131 (MDA MB436),
GSM1589153 (MDA MB231), GSM275993 (MDA MB231), GSM1589152 (MDA
MB157). Summaries of which cell lines are grouped together for comparison are outlined
in Table 2 above. Individual cell lines used for the Cluster analyses were obtained from the
GSE12777 dataset obtainable at GEO.
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Microarray Procedural Outline: As summary, the microarray platform can be
used to determine the transcript levels of RNA preparations (i.e., cell line preparations).
The technique is used to interrogate the expression levels of a large number of genes at the
same time, allowing for comparative transcriptome and signaling analyses between
different samples. DNA microarrays (sometimes called gene-chips) are cassettes that
consist of printed spots containing known DNA sequences. The DNA sequence
corresponds to specific regions of a gene that can be used to probe for detection of that
gene (25).

Figure 7:

Diagram of a Gene Expression Array Illustrating How Biotin-labeled
RNA Fragments (purple) Hybridized to DNA Probe Array (green) (29).

RNA is extracted from cells during log phase. mRNA transcripts are converted to
antisense, end-labeled and hybridized to their complement sequence which is immobilized
to a high-density gene-chip cassette. Probe-sets (i.e., sequences on the cassette) are
positioned within microns of each other. For this particular microarray, the color ranges
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from black which corresponds to zero or low levels of transcript detected to white, which
corresponds to high copy number transcript; see the yellow insert.
The sense form of the gene is spotted and immobilized onto the cassette, which can
be used to hybridize and detect the corresponding fluorescently labeled antisense
complement (Figure 7). The amount of hybridization and subsequent florescence can be
used to determine copy-number (based on comparisons to internal controls).

The

Affymetrix microarray platform is the most widely used microarray platform for full
genome expression analysis and is the platform employed in my project (25).
.

Figure 8:

Example of Gene Expression Data Generated from Microarray Gene
Chips (29)

Approximately 50,000 genes are compared across four microarrays. Transcript
levels are displayed as log2 values. A pseudo-color can be used to correspond to gene
transcript copy number. The colors differ depending on the user preference. Colors in this
figure range from black which represents transcript levels near zero, to bright green which
corresponds to high transcript copy number.
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One microarray cassette or gene-chip is used for each sample. After the sample is
hybridized to the array and analyzed by the software, the data is normalized, compared to
internal controls and transcript levels for each sample are displayed (row-by-row) allowing
the genes on different microarrays to be directly compared (Figure 8). The values given in
Figure 7 represent log 2 values corresponding to the transcript levels for 4 different
samples, for ~50,000 gene transcripts. For my experiments, we downloaded cell lines
processed using the Affymetrix U133 plus 2.0 microarrays which contained 54,676
transcripts and transcript variants.
Data Analyses
MAdB Online Database
mAdB is a private online data analyses resource supported by NCI. mAdB contains
data analyses tools suitable for miRNA, genomic, transcriptome, pathway, and other types
of bioinformatic tools (mAdb.nci.nih.gov). The TNBC cell line microarray datasets were
uploaded from GEO to mAdB. I used mAdB to determine which genes from Basal A cell
lines (CA-HCC1143, CA-HCC1187, AA-MB468, AA-HCC70) and from Basal B cell
lines (CA-MDA-MB231, CA-MDA-MB436, AA-MDA-MB157) possessed the greatest
degree of transcript copy number difference in expression level (i.e., differential
expression) (30). Refer again to Table 2 for a summary of the comparisons. To compare
Basal A samples, CA was designated as group 1 and AA was designated as group 2 and Ttest with unequal variance was applied. Separately to compare Basal B samples, CA was
designated as group 1 and AA was designated as group 2 and T-test with unequal variance
was applied (Figure 9, Figure 10).
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Figure 9:

Snapshot of the mAdb Two-group Test Program Interface (30)

Figure 10: Snapshot of the mAdb 2 Group Statistic Analysis Automatically
Selected for a 2-group Dataset (30)

T-test Group Analyses
To identify differentially expressed genes (i.e., a list of genes with expression levels
statistically and (more important) biologically different in two or more sets of the
representative transcriptomes) a T-test group analysis was done. The t-test group analyses
determine whether the means of two groups are statistically different. Following t-test
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analyses, gene are selected for further analyses if there is at least a 2-fold difference
between transcript levels, with p-value <0.05; this is the industry accepted criteria for
reliable differentially expressed genes using the microarray platform.
Conserved Domain Analyses
The National Center for Biotechnology Conserved Domain (CD) Blast search tool
(31) was used to perform CD analyses. The CD analyses was utilized to identify conserved
sequence motifs present in differentially expressed genes. CD similarities imply functional
similarity between different genes and proteins.
Signaling Pathway Analyses
Signaling pathway analyses were performed using mAdB.
STRING protein: protein interaction AnalysisRetrieval of Interacting Genes/Proteins (STRING) is used to determine the
relationship between proteins based on millions of data points related to experimental data,
computational prediction methods and public text collections (32).
Hierarchical Cluster Analysis of TCEALs:
The hierarchical (HC) analyses were used to determine genes similarly expressed.
This was performed using mAdB.
Multalin Analysis of TCEALs
Multalin is an online sequence analysis program. Multalin sequence analysis was
used to validate the CD of differentially expressed genes (32). Multalin was performed by
submitting the gene sequences to the online server.

CHAPTER 4
RESULTS AND DISCUSSION
As mentioned, two separate analyses were performed, AA vs CA based on the Basal
A molecular distinction and AA vs CA based on the Basal B distinction. The data were
generated using the DNA microarray platform which allows for comparative analyses of
gene transcript levels. An example of these data is presented in Tables 3 and 4. The T-test
was used to identify differences between the ethnicities. The T-test analysis compares the
average gene expression levels between the two patient populations. The comparison
values are plotted under the A-B mean difference column. T-test generates the fold change
and the significance (of this change) in the form of the p-value. The data can then be sorted
based on fold change and p-value. The industry standard for selecting differentially
expressed genes in microarray is p-value of <0.05, with a fold change of >2.0. Even though
the microarray initially contained 54,000 genes, most of the genes were not different
between the populations; so, filtering based on p-value and fold change led to a
substantially smaller list of genes. These genes were considered differentially expressed.
As example of how the comparisons are presented after processing, see Table 3 and Table
4. After a shorter gene list is generated the tables can be transported into Excel, so
additional sorting can be when performed. Cell line designations are included in the
headings.
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Table 3: T-test Basal A Group
Analysis comparing CA cell lines (1-3) to AA cell lines (4-7). Blue are CA
and red are AA cell lines.

Table 4: T-Test Basal B Group
Analysis comparing CA cell lines to AA cell lines. Blue are CA (1-3) and red
is the only AA cell line present (4-5). The program does not allow 1 sample,
so the data were repeated.

Table 3 and 4 are examples of the T-test group analyses data. The values in table
(corresponding to each gene) represent the normalized transcript level for each gene. Only
a portion of the table is displayed as an example. Table 3 shows an example of comparisons
between the Basal A subcategory containing CA cell lines (in blue; 1-3) and the AA cell
lines (4-7; red). Table 4 shows an example of the comparisons between the Basal B subcategory containing CA cell lines (in blue; 1-3) compared to the only AA cell available (in
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red; 4-5) for the Basal B sub-category. For both tables, to the right of each area the
significance p-value and the and the mean difference between each gene is noted by A-B
p-value and A-B mean, respectively. The A-B mean represents the fold difference in
transcript level for a particular gene. The gene symbol is in the final column. The
comparisons were generated by --“CA divided by AA”.
After the data were filtered (based on p-value and fold change), < 500 genes were
generated. Built into mAdB is a function that will filter for background noise or
questionable gene values. Using this program function, an even smaller, more manageable
gene list is generated. Gene lists can be processed in Excel and online analyses tools like
Molbiotools can be used to compare gene lists
(http://www.molbiotools.com/listcompare.html).

Short List of Genes Common to Basal A and Basal B
There were a few genes common to both datasets, for example genes generated by
comparing CA vs AA Basal A genes; and genes generated by comparing CA vs AA Basal
B genes (Table 5). The short list of genes was identified using the online tool
(http://www.molbiotools.com/listcompare.html). These genes were common to Basal A
and Basal B. Most of the genes were not the same but likely belong to the same gene family.
A table of the genes that were common across Basal A and Basal B along with their
differential gene expression levels are described in Table 6. The values represent a
comparison between CA vs AA, so if the value is positive that means the gene is
downregulated in AA compared to CA, and if the value is negative the gene is high in AA.
Ideally, we searched for the exact same gene on both Basal A and Basal B cell lines that
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showed the same direction of differential expression (if down-regulated in Basal A then
also down-regulated in Basal B). That would suggest “a sort of AA gene”. Because we did
not find this gene, it could be that (a) no such gene exists or (b) there are significant
differences between Basal A and Basal B that ‘different AA genes drive or, are associated
with the signaling processes in the 2 sub-categories. Even though CCDN1, CYP4X1 and
SUSD2 genes satisfied this requirement, when we examined the genes further and
compared them to independent datasets of CA cell lines (i.e., MDA MB231; Dr Player’s
datasets), the genes did not show the same pattern of expression, in other works, the results
were not reproducible.
Table 5: Short-list from Basal A and Basal B
Analyzed to determine common genes between both cell lines. Using this
online tool-Molbio-Tools (http://www.molbiotools.com/listcompare.html)

BASAL B genes

BASAL A genes

CCND1
CLDN10
CYP4X1
EEF7
EIF4EBP1
HIST1H2BG
HIST1H2BG
SUSD2
TCEAL8

CCND1
CLDN8
CYP4X1
E2F5
EIF5A
HIST1H2BD
SUSD2
TCEAL9
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Table 6: Table of Common Genes
Showing their direction of differential expression (If up-regulated in Basal A
then up-regulated in Basal B).

When we compared separately, Basal B- CA vs AA, and Basal A- CA vs AA, we
identified the genes given in Table 7. We will refer to these as our candidate genes. The
gene, its fold-change, significance value, direction of change (i.e., either high or low in
AA) and gene description are noted. The APOE gene is indicated, not because it’s a reliable
candidate, but to serves as example of a gene that is high in 1 condition and low in another.
It’s important to point out that both Basal A and Basal B contain differentially expressed
TCEAL genes, TCEAL9 in Basal A and TCEAL 8 in Basal B. Both TCEAL genes show
lower gene expression levels in African-Americans. The TCEAL genes belong to the same
gene family and are functionally related making them candidates as African American
associated genes. The functional domain studies discussed later will support this
hypothesis. Figure 11 is a graphical representation of Table 7. For our candidate genes.
Caucasian expression levels are in gray and African American expression levels are in
gold. I want to note that the genes that I selected are candidate genes based on preliminary
analysis. The genes will be analyzed further by polymerase chain reaction and western
analyses for protein, and if available, tissue microarray to examine protein levels in patient
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samples. Based on analyses, there are no associations, pathway signaling or otherwise
connecting TCEAL8, TCEAL9, EFDH1 and PEG3.

Table 7: Low and High Differentially Expressed Genes
Notes included in the table indicate if the genes were either low or high in AA
cell lines.

Figure 11: Graph Showing Level of Gene Expression of Our 5 Differentially
Expressed Genes
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The EFHD1 was also selected as a candidate gene. The gene is an EF-hand Ca++
binding gene associated with mitotic events and synaptic transmission. The gene was
chosen mainly because it was identified as differentially expressed in TNBC patient
samples; similarly, for PEG3. The patient sample data are presented later. In a separate
study, Ruiz-Narváez et al (33) identified what they termed a breast cancer susceptibility
locus, 2q37.1 in African American women. The article Admixture Mapping of African
American Women in the AMBER Consortium Identifies New Loci for Breast Cancer and
Estrogen-Receptor Subtypes is the largest of its kind including thousands of patients many
which are African American. The authors did not identify genes at this locus. We are
interested in this study because the EFHD1 identified in our study is located at 2q37.1. The
EFHD1 gene is downregulated in Basal B AA women and might be mutated in these
patients leading to loss of heterozygosity. We will continue these analyses.
Cluster Analysis Validating Cell Line Data
We also performed a cluster analysis of our genes (Figure 12). The cell lines
included all molecular subtypes of breast cancer. Our candidate genes are designated
across the top of the cluster and cell lines are along the side. Based on a particular gene,
the program determines and compares the transcript levels of that gene in the various cell
lines. All of the cell lines were obtained from the GSE12777 microarray study to eliminate
potential bias that might occur when comparing cell lines from different studies. Transcript
levels are coded in red or blue. Red represents high transcript levels and blue represents
lower levels for a gene. Based on analyses, there are no associations, pathway signaling or
otherwise connecting TCEAL8, TCEAL9, EFDH1 and PEG3.
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Figure 12: Clustergram of our 5 Differentially Expressed Genes in Diverse Breast
Cancer Cell Lines Including Luminal A/B, Her2neu, TNBC, Normallike

The cell lines and the genes that cluster closer together are more closely related
(based on molecular characteristics), those farther apart are more different (31).
Interestingly, all of the African American samples clustered in the upper region of our
clustergram shown by the top three arrows with red boxes, and all of the Caucasian samples
clustered in the lower region of our clustergram shown by the lower four arrows. At first
thought, we assumed that Basal A would cluster together, and Basal B would cluster
together, irrespective of ethnicity. But the clustergram depends on the genes being
analyzed. This particular clustergram is considered a ‘supervised analyses’ where the
investigator determines the genes to process. Based on this analysis, these data validate
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that AA cell lines are more closely related to each other. Modifications to the samples or
the genes will generate a different response/answer.
T-Test Analysis of Patient Samples
We further validated our cell line data by analyzing the same genes in patient
samples. We were able to find a microarray dataset containing AA vs CA TNBC patients.
This is not a perfect dataset (for us) because the patients are not characterized by Lehmann
classification. They were identified as CA TNBC and AA TNBC. Patient samples were
selected from GDS3097 based on ER/Her2 negative receptor status. Nonetheless, we
performed the analyses using the usual T-test. Results from this comparison are included
in Table 8. The datasets also differ from those described above in that a different microarray
platform was used. These authors used the older U133A microarray which contained
22,000 genes and probe-sets compared to the higher density (54,000 probe-set) microarray
used for all the previous analyses. The TCEAL genes are not on this array, so they can not
be analyzed.
We performed a T-test analysis using the same filter criteria as before (i.e., p-value
<0.05- and 2-fold differential gene expression). Two of our candidate genes were identified
in this dataset, including the PEG3 and the EFHD1 genes, similar to our cell line data. It’s
important to reiterate that there are limitations to using this patient sample dataset. The
samples are not stratified based on Lehman classification like the cell lines used in our
previous analyses. Still PEG3 and EFHD1 are identified as differently expressed in African
American patient samples vs Caucasian patient samples. We were encouraged by these
findings.
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Table 8: Patient Sample T-Test
T-test group analysis of patient samples. Validation of cell line data in actual
patient samples (CA red vs AA black)

A-B Mean
Feature
Gene
A-B Difference
ID
p-Value
506.7 0.0023815 -2.2434 203962_s_NEBL
42.3 0.0037024 -3.5366 205030_atFABP7
157.0 0.0043409 -2.4228 209369_atANXA3
1620.0 0.0072156 -3.1714 209242_atPEG3
106.5 0.0081671 -2.1244 205110_s_FGF13
14.0 0.011401 -2.4087 205029_s_FABP7
22.4
0.0138 -2.1342 204913_s_SOX11
583.6 0.01462 -2.0340 212328_atLIMCH1
444.0 0.017942
2.5006 209396_s_CHI3L1
652.3 0.02331 -2.0274 209343_atEFHD1
147.6 0.024012 -2.1195 204875_s_GMDS

SM136394 SM136400
C
SCM136412 SM136387
C
SAM136391 SM136406
A
SM136413
A
SAM136416 SAM136417 SAM136418 SAM136420 A
94.6
64.1
72.1
44.5
57.0
14.7
50.7
43.9
779.7
165.7
83.6

53.4
55.4
32.4
39.2
73.4
23.0
28.6
78.7
2611.5
493.1
27.1

46.7
50.6
32.0
115.6
142.2
15.4
19.2
122.5
1035.8
284.6
36.8

80.0
4901.0
58.1
1797.2
416.7
862.9
186.9
56.9
87.6
740.0
94.0

121.0
1594.4
213.0
409.5
1018.3
121.2
170.5
154.7
213.8
819.4
467.0

620.0
1521.1
441.6
162.9
1033.8
186.7
319.2
866.2
187.8
1551.9
376.1

470.2
557.4
370.6
1374.0
266.9
49.2
95.9
489.5
194.3
735.7
112.6

700.6
479.5
483.7
3267.3
376.6
68.3
53.9
324.4
180.3
1459.1
182.6

205.6
98.4
192.8
49.3
255.5
18.7
752.5
351.3
166.6
2677.6
269.9

260.7
2561.1
230.0
141.7
272.4
298.2
109.9
321.6
763.2
1904.7
125.2

.
Further Analyses of the TCEAL Family of Genes:
The TCEAL genes belong to a family of transcription elongation factor genes. The
gene family is characterized as having a brain expressed linked family (BEX) functional
domain. The BEX1 domain is thought be associated with genes involved in cell cycle and
signaling, neuronal differentiation and general responses to external signaling events. All
TCEAL genes contain the BEX domain. The TCEAL genes are small with slight variations
in sequence and length and interestingly they are located on the chromosome X. Our data
show TCEAL8 and 9 downregulated in AA TNBC. Interestingly, a study by Huo et al.
identified TCEAL7 associated with TNBC. The study “Comparison of Breast Cancer
Molecular Features and Survival by African and European Ancestry in The Cancer
Genome Atlas was performed by Huo and Charles Perou (34). The authors identified 142
genes as differentially associated with AA women and TCEAL7 was one of the genes.
TCEAL7 is also a member of the TCEAL gene family.
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STRING Analyses of TCEAL Proteins
We identified both TCEAL genes downregulated in AA TNBC cell lines. TCEAL8
was downregulated in Basal B, and TCEAL9 was downregulated in Basal A cell lines. We
suggest that TCEAL8 might function in Basal B, and TCEAL9 performs the same function
in Basal A. To examine if the proteins have been characterized as functionally similar, we
performed the STRING assay (32) string.db.org) (8) . STRING program interrogates
millions of data points based on (a) if particular genes have been sited in the same
publication and (b) if the genes have been experimentally determined to interact via any
experimental method. The STRING analyses demonstrate a close relationship between
TCEAL8 and TCEAL9 (WBP5). The WBP5 gene is another designation for TCEAL9.
Analysis determined that TCEAL 8 and TCEAL 9 genes from our list of candidate genes
are functionally related. It could be that TCEAL8 involved in signaling mechanisms in
Basal B and TCEAL9 is involved in signaling mechanisms in Basal A. STRING displays
a low (i.e., high confidence, statistically significant value) for TCEAL8 and TCEAL9
involvement in downregulation of elongation functions. These results must be analyzed
further, and experimental comparisons performed via polymerase chain reaction. TCEAL7
was not found associated with TCEAL8 and 9. There are no associations, signaling or
otherwise connecting TCEAL8, TCEAL9, EFDH1 and PEG3.
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Figure 13:

STRING to Demonstrate Functional Relationship between TCEAL9
(WBP5) and TCEAL8
Red balls represent genes involved in decreased expression of transcription
elongation. Significant strength.

TCEAL Comparison Analysis Using BLAST, Conserved Domain and
Multialin BLAST Analysis of TCEALs
The Multalin program is used to perform sequence alignment. TCEAL 8 and
TCEAL

9

genes

were

subjected

to

analyses

at

the

following

website

(http://multalin.toulouse.inra.fr/multalin/) (28) Figure 14. The multalin software allows
simultaneous alignment of several biological sequences so that similarities in the sequences
are juxtaposed (28). These comparisons show NP_699164.1 (TCEAL8) and NP_057387
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(TCEAL9) are closely aligned in the BEX family domain (at ~position 90). The TCEAL7
protein differs at this domain by 2 amino acids (instead of RV there are amino acids GL).

Figure 14: Multalin data Comparing the Sequence Alignment of TCEAL 8 and 9
Protein
The common functional domain is amino acids positions 88-96.
As mentioned, from a functional standpoint TCEAL8 and TCEAL9 genes are
closely related, they are both on the X-chromosome, both elongation factors, and when you
compare their functional domains, they are the same. The functional domain of a protein
will define how proteins work, which might explain why both TCEAL 8 and TCEAL9
show low expression levels in our cell line data. We performed a BLAST analysis of
TCEAL8 to determine genes with similar homology
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) (27). With TCEAL8 as the input gene, the
program automatically searches for sequence homology based oh homo sapiens (because
we limited the analyses to humans). Table 9 show the TCEAL genes are the highest
‘confidence’ genes similar to TCEAL8 which include TCEAL9, TCEAL7 and two
TCEAL1 genes. We recognize that for any particular protein a number of functional
domains exist. So for TCEALs, there are likely uncharacterized domains present. Maybe
its coincidental that the TCEALs are downregulated in the AA cancers and the function of
the gene is independent of functions related to BEX. These data only serve as preliminary
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data, and we understand that additional data analyses and definitely experimental studies
must be done.

Table 9: Conserved Domain Data of TCEALS
Conserved domain data showing that TCEAL 7 and 9 have a high association
to TCEAL 8

.
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Figure 15: Domain Analyses of TCEAL Family Genes
The top 5 lines include sequence similarity between TCEAL8, TCEAL7,
TCEAL9, 2 similar-TCEAL1.

CHAPTER 5
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
We have identified 4 different genes (excluding APOE) that are differentially
expressed meaning they show different expression levels in African American women cell
lines to Caucasian TNBC cell lines. We believe that these differences in expression levels
are significant. We validated our genes using a number of different methods, so we have
confidence in our discovery. At this point the study is exclusively a bioinformatic study,
but we have plans to expand the study and include experimental transcript and protein
expression studies as validation. Whether these data will validate experimentally remains
to be determined.
.
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